Clinical TrialJun 18, 2026, 08:01 AM
Allarity to Present Stenoparib Phase 2 Ovarian Cancer Trial Poster at ESMO
AI Summary
Allarity Therapeutics announced it will present a Trial-in-Progress poster for its ongoing Phase 2 study of stenoparib (2X-121) at the ESMO Gynaecological Cancers Congress 2026. The poster will detail the scientific background, study design, and clinical rationale for evaluating stenoparib, a dual PARP and WNT pathway inhibitor, in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. This presentation aims to highlight the drug's potential and the company's DRP® patient selection approach to a specialized audience, building on prior Phase 2 experience that showed durable clinical benefit.
Key Highlights
- Allarity to present a Trial-in-Progress poster at ESMO Gynaecological Cancers Congress 2026.
- Poster outlines Phase 2 trial of stenoparib in advanced platinum-resistant or platinum-ineligible ovarian cancer.
- Stenoparib (2X-121) is a novel dual PARP and WNT pathway inhibitor.
- Study builds on prior Phase 2 experience showing durable clinical benefit in ovarian cancer patients.
- Principal Investigator Kathleen N. Moore, M.D., will present the poster.
- The company's DRP® patient selection approach will be highlighted.
- A separate Phase 2 trial for stenoparib in small cell lung cancer began enrolling in early 2026.
Price Impact
More from ALLR